Reducing adverse events associated with the glucagon stimulation test for the assessment of growth hormone deficiency in adults with a high prevalence of pituitary hormone deficiencies
| Autor: | Carmela Caputo, Maresa M. Derbyshire, Katerina V Kiburg, Caroline Jung, Reetu Gogna, Balasubramanian Krishnamurthy, Margaret Zacharin, Kylie McLachlan, Nirupa Sachithanandan, Richard J MacIsaac, Alice Hong |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
medicine.medical_specialty Nausea Endocrinology Diabetes and Metabolism 030209 endocrinology & metabolism Gastroenterology Growth hormone deficiency 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine Post-hoc analysis Prevalence medicine Humans Dwarfism Pituitary Adverse effect Retrospective Studies Hydrocortisone Human Growth Hormone business.industry Glucagon medicine.disease Growth Hormone 030220 oncology & carcinogenesis Cohort Vomiting medicine.symptom business Glucocorticoid medicine.drug |
| Zdroj: | Clinical Endocrinology. 95:125-133 |
| ISSN: | 1365-2265 0300-0664 |
| Popis: | DESIGN A retrospective review of the adverse events (AEs) in 78 patients during the glucagon stimulation test (GST) for the assessment of growth hormone deficiency (GHD) before and after protocol amendments which aimed to reduce AEs in a group of patients with a high prevalence of pituitary hormone deficiencies. PATIENTS Based on our observations of frequent AEs during the standard GST protocol in an initial 25 patients (cohort 1), a modified protocol was introduced to include the routine administration of 20 mg of hydrocortisone pre-GST in a subsequent 53 patients (cohort 2). Post hoc analysis of the effect of glucocorticoid dosing pre-GST on AEs was examined in those receiving |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text